In a recent phase 3 clinical trial of nemolizumab, 58 percent of participants with moderate to severe prurigo nodularis had significant, lasting itch relief after 16 weeks of use. After 24 weeks, nearly 31 percent had total or near-total skin clearance.

Approved by the U.S. Food and Drug Administration (FDA) in 2024 for prurigo nodularis under the brand name Nemluvio, nemolizumab is an interleukin (IL)-31 receptor antagonist. It works by blocking IL-31 signaling, a key contributor to itch and inflammation. It’s given as a prefilled subcutaneous (under the skin) injection once every four weeks.

In the trial, around 58 percent of participants had a reduction in itch severity by week 16, compared to about 16 percent who received a placebo (inactive treatment). This level of relief was maintained at 24 weeks.

Participants also saw sustained improvements in skin clearance. By 16 weeks, 26 percent of people treated with nemolizumab achieved near-total or total clearance of lesions, compared to 7 percent of people in the placebo group. By week 24, this increased to around 30 percent in the nemolizumab group, compared to 9 percent in the placebo group.

Side effects were mild to moderate and included headache and eczema.

Potential for Long-Awaited Prurigo Relief

Several treatment options are available for managing prurigo nodularis, including steroids, over-the-counter topicals, and prescription-strength vitamin D. Only recently has the FDA approved medications such as dupilumab (Dupixent) and nemolizumab that are specifically indicated for the condition and may bring relief when other treatments have fallen short.

The results of this study suggest that nemolizumab, a relatively new treatment, may bring much-needed relief to people with prurigo nodularis who previously had few options. The drug may offer improvements in itch severity, skin clearance, and sleep. However, it’s important to note that it may not work for everyone, and side effects can occur.

If you’re living with prurigo nodularis, consider speaking with your healthcare provider to explore whether nemolizumab or other treatments could be right for you. Your provider can help tailor a treatment plan to address your unique needs and symptoms.

Read more about treatment options for prurigo nodularis.

Find Your Team

On MyPrurigoTeam, the social network for people living with prurigo nodularis and their loved ones, members come together to ask questions, give advice, and share their stories with others who understand life with this condition.

What has helped you manage the itching and nodules of prurigo nodularis? Have you tried any newer treatments? Share your tips and experiences in a comment below, or start a conversation on your Activities page.